Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) is a healthcare technology company focused on intelligent medication management, and the OMCL news page on Stock Titan aggregates company-specific updates that matter to investors and healthcare observers. Omnicell describes itself as a leader in transforming the pharmacy and nursing care delivery model, with solutions that combine automation, AI-enabled intelligence, and expert services to support clinical, operational, and financial outcomes across all settings of care.
News related to Omnicell often centers on financial results, product innovation, and strategic developments. The company regularly issues earnings releases and guidance updates, discussing performance across categories such as connected devices, technical services, SaaS and Expert Services, and consumables. Press releases also cover events like conference presentations, investor Q&A sessions, and participation in industry meetings, providing context on how management communicates its strategy and outlook.
Product and technology announcements are another key theme in OMCL news. Examples include the launch of Omnicell Titan XT, an enterprise automated dispensing system powered by the OmniSphere cloud platform, and updates on OmniSphere certifications and capabilities. Omnicell also highlights initiatives such as specialty pharmacy services, URAC Health Care Management Certification, and innovation-focused events like Omnicell Illuminate and the IV TRUST Summit, which showcase developments in robotics, smart devices, software workflows, and data and analytics.
By following OMCL news, readers can monitor how Omnicell advances its vision of autonomous medication management, how it positions its solutions for health systems, retail and specialty pharmacies, and how management addresses risks and opportunities in a regulated healthcare environment. The Stock Titan news feed helps users track these announcements in one place for ongoing reference.
Omnicell (OMCL), a company focused on pharmacy care delivery transformation, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 1:30 p.m. PT.
Interested parties can access both live and archived versions of the presentation through the company's investor relations website at their events and presentations page. This participation in one of healthcare industry's premier conferences demonstrates Omnicell's continued engagement with the investment community.
Omnicell (Nasdaq:OMCL) has announced OmniSphere, a next-generation, cloud native software workflow engine and data platform designed to integrate enterprise robotics and smart devices for medication management. The platform aims to provide state-of-the-art security, improved productivity through single-point access, and enterprise-wide medication inventory visibility.
The company also revealed that its XT Amplify program solutions, including MedChill and XTExtend, are OmniSphere-ready. Additionally, MedChill now integrates with Follett refrigerators for temperature-controlled medications. Omnicell has also developed new DSCSA interface options with TrackTraceRX and LSPedia for its Central Pharmacy Manager software.
Omnicell (Nasdaq: OMCL), a leading pharmacy care delivery model transformation company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 2:00 p.m. ET. Both live and archived versions of the presentation will be accessible to interested parties through Omnicell's investor relations website in the events and presentations section.
Omnicell has announced the pricing of $150 million of 1.00% Convertible Senior Notes due 2029. The notes will mature on December 1, 2029, with interest payable semiannually at 1.00% per annum. The initial conversion rate is 17.4662 shares per $1,000 principal amount, equivalent to $57.25 per share. The company expects net proceeds of approximately $144.2 million, which will be used to repurchase $400 million of existing 2025 notes and fund convertible note hedge transactions. The offering includes additional options for purchasers and various hedging arrangements to manage potential dilution.
Omnicell (NASDAQ: OMCL) announces plans to offer $150 million of Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. The company will grant initial purchasers an option for an additional $22.5 million. The notes will be senior unsecured obligations with semiannual interest payments. Omnicell plans to use the proceeds to fund convertible note hedge transactions and repurchase up to $400 million of its outstanding 0.25% Convertible Senior Notes due 2025.
Omnicell (NASDAQ:OMCL) reported Q3 2024 results with total revenues of $282 million, down 5% year-over-year. GAAP net income was $9 million ($0.19 per diluted share), compared to $6 million ($0.12 per diluted share) in Q3 2023. Non-GAAP net income reached $26 million ($0.56 per diluted share). The company raised its 2024 non-GAAP EBITDA and earnings guidance, expecting full-year revenues between $1.100-1.110 billion and non-GAAP earnings per share of $1.65-1.72.
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, has announced the release of its third quarter 2024 financial results. The results will be disclosed before market open on Wednesday, October 30, 2024. Following the release, the company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial outcomes.
Interested parties can participate in the live call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for international locations, using the Conference ID 6944646. Additionally, a link to the live and archived webcast will be available on the Investor Relations section of Omnicell's website.
Omnicell, Inc. (Nasdaq: OMCL) has appointed Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024. In this newly created role, Njoku will lead the company's global operations, reporting to Randall Lipps, chairman, president, CEO, and founder of Omnicell.
Njoku brings approximately 25 years of experience in leading global operations at healthcare and medical technology organizations. He most recently served as President of Sports Medicine, Surgical, Upper Extremities and Restorative Therapies at Zimmer Biomet Holdings, Inc. Previously, he spent over 18 years at Medtronic plc, where he led a $2 billion Neuromodulation Operating Unit.
Omnicell, a leader in transforming the pharmacy care delivery model, expects Njoku's expertise to help scale pharmacy automation and drive multi-year innovation and excellence.
Omnicell (Nasdaq: OMCL) has unveiled its Central Med Automation Service, a subscription-based solution designed to help health systems optimize centralized medication management. This service integrates enterprise-wide robotics, smart devices, and intelligent software with expert services to streamline medication dispensing from central fulfillment areas throughout health system enterprises.
Key components include the XR2 Automated Central Pharmacy System for advanced medication storage and dispensing, Central Pharmacy Manager software for workflow support, and Inventory Optimization Service for enterprise-wide inventory management. The service also provides ongoing expert guidance, on-site support, and performance tracking to ensure continuous operational optimization.
This solution aims to enhance inventory visibility, scalability, and patient safety while addressing challenges such as drug shortages and staffing issues in pharmacy operations.
Omnicell, a leader in pharmacy care delivery transformation, has announced its participation in the 2024 Wells Fargo Healthcare Conference. The company, trading under the Nasdaq symbol OMCL, will present on Thursday, September 5, 2024, at 1:30 p.m. ET.
This event provides an opportunity for investors and industry professionals to gain insights into Omnicell's strategies and innovations. Both live and archived webcasts of the presentation will be accessible through the company's investor relations website, offering wide-ranging access to interested parties unable to attend in person.
The conference, hosted by Wells Fargo, is a significant platform for healthcare companies to showcase their developments and future plans to the investment community.